WPG Advisers’s Syndax Pharmaceuticals SNDX Stock Holding History

WPG Advisers’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11	Closed	-$135	–	1494
2025 Q1	$135	Buy	+11	New	+$155	﹤0.01%	1415

Other funds holding SNDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

WPG Advisers's SNDX Position: Q2 2025 in Review

WPG Advisers sold out of Syndax Pharmaceuticals (SNDX) in Q2 2025, closing a stake of 11 shares — an estimated $135 sold.

WPG Advisers first reported a position in SNDX in Q1 2025 and held it in 1 quarter. The position peaked at $135 in Q1 2025. 216 funds tracked by Wall St. Rank hold SNDX as of Q2 2025.

WPG Advisers reported no remaining Syndax Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
WPG Advisers sold 11 Syndax Pharmaceuticals shares in Q2 2025, an estimated $135.
WPG Advisers first reported a position in Syndax Pharmaceuticals in Q1 2025 and held it in 1 quarter.
WPG Advisers's Syndax Pharmaceuticals position peaked at $135 in Q1 2025.
216 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2025.

Based on WPG Advisers's 13F filing for Q2 2025, filed 11 Aug 2025.